Zealand Pharma A/S (OTCMKTS:ZLDPF) Reaches New 1-Year Low - Should You Sell?

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) reached a new 52-week low on Tuesday . The stock traded as low as $78.50 and last traded at $79.38, with a volume of 1552 shares trading hands. The stock had previously closed at $83.90.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on ZLDPF shares. JPMorgan Chase & Co. initiated coverage on Zealand Pharma A/S in a research report on Friday, November 8th. They set an "overweight" rating on the stock. Cantor Fitzgerald upgraded Zealand Pharma A/S to a "strong-buy" rating in a research report on Tuesday, January 21st. Finally, William Blair upgraded Zealand Pharma A/S to a "hold" rating in a research note on Thursday, February 27th.

Zealand Pharma A/S Stock Performance

The firm has a market cap of $5.47 billion, a P/E ratio of -32.63 and a beta of 0.92. The stock's 50 day moving average is $98.87 and its two-hundred day moving average is $110.66. The company has a debt-to-equity ratio of 0.03, a current ratio of 35.49 and a quick ratio of 35.49.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last announced its earnings results on Thursday, February 20th. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.19. The business had revenue of $1.30 million for the quarter, compared to analysts' expectations of $28.11 million. Zealand Pharma A/S had a negative return on equity of 15.24% and a negative net margin of 1,725.03%. As a group, equities analysts predict that Zealand Pharma A/S will post -2.19 EPS for the current year.

Remove Ads

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.